CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The CCTG Annual Spring Meeting is only 6 weeks away! Don't forget that the request an invitation portal closes April 7 and online registration closes April 9.
Another successful CCTG Spring Meeting of Participants ended with ~900 network members, international friends and sponsors contributing to sessions and workshops to propose new trials and review current portfolio of activities. It was hectic but also inspirational.
Findings from the CCTG PR13/RADICALS-HD study confirm that adding two years, compared to six months of hormone therapy delays prostate cancer spread in people who had surgery to remove the prostate followed by radiotherapy.
A longer follow-up from the PR13/RADICALS-RT international study confirms that having radiotherapy only if the cancer returns, as opposed to having it soon after surgery, is a better approach for most people.
BRC2 (E1505): A phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/= 4 cm) – III a non-small cell lung cancer (NSCLC) trial. NCT00324805: Results are available on www.clinicaltrials.gov
We are very honoured to present Jim Julian from McMaster University with the Excellence in Clinical Trials Conduct award which was graciously received by Jim at the CCTG Spring Meeting. The award is presented to an individual who exemplifies excellence in clinical trial operations and compliance.
"I would like to thank the CCTG and the DSMC Chair and Secretary for considering me for such an honour. I am happy to accept this recognition award.
The Phase III Team Award for CCTG-Led Trials was presented to the PR21 team from the BC Cancer at the Annual Spring Meeting this past weekend.
Congratulation to CCTG's very own Dr. Philippe Jamme who was presented the Elizabeth Eisenhauer Early Drug Development Young Investigator Award for his IND study contributions. The award was presented at the CCTG Spring Meeting this past weekend.
